Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.47 |
| ▸ | CCND1 | P24385 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30233726 | 1.00 | CDK4 (0.47) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL30233822 | 0.86 | CDK4 (0.42) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL7987460 | 0.82 | CDK4 (0.42) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL5236935 | 0.82 | CDK4 (0.41) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL30388872 | 0.81 | CDK4 (0.43) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL29617408 | 0.79 | TSHR (0.46) | CDK4CCND1KMT2AALDH1A1TSHR | |
| SCHEMBL3334839 | 0.79 | TSHR (0.46) | CDK4CCND1KMT2AALDH1A1TSHR | |
| SCHEMBL321199 | 0.78 | CDK4 (0.45) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL4288131 | 0.78 | CDK4 (0.45) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL29614841 | 0.78 | CDK4 (0.45) | CDK4CCND1HTR2AHTR2CNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006014-B1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2022-12-20 | — | — | US | disclosed |
| EP-4006014-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | Medshine Discovery Inc. (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2022010352-A1 | 5-HYDROXYINDOLE AND ANALOGS THEREOF AS STIMULANTS OF GUT MOTILITY | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021018017-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
| EP-3724183-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118799-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-20 | — | — | WO | disclosed |
| US-7645753-B2 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-100393309-C | Use of alpha-thiophenylcarboxylic and alpha-phenoxycarboxylic acids with serum glucose lowering and serum lipid lowering activity | SIGMA TAU IND FARMACEUTI (IT) | 2008-06-11 | — | — | CN | disclosed |
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | US | disclosed |
| CN-1728992-A | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA TAU IND FARMACEUTI (IT) | 2006-02-01 | — | — | CN | disclosed |
| US-6238439-B1 | DYEING HAIR WITH IODIDE-FREE, TWO-COMPONENT DYE COMPRISING INDOLE COMPOUND AND AN AQUEOUS ALKALINE OXIDIZER SOLUTION OF HYDROGEN PEROXIDE, UREA PEROXIDE, A PERCARBONATE OR A PERBORATE | L'OREAL (FR) | 2001-05-29 | — | — | US | disclosed |
| US-4099972-A | DIFFUSION TRANSFER | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1978-07-11 | — | — | US | disclosed |
| US-3974041-A | Image recording member with zeolitic water containing compounds | CANON KABUSHIKI KAISHA (JA) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | SSTR5, SSTR1, SSTR2 | CDK4 804/4885CCND1 897/4885HTR2A 269/4885 |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | ERBB2, ERBB3, EGFR | CDK4 119/4885CCND1 837/4885HTR2A 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.